Inogen (INGN) Liabilities and Shareholders Equity (2013 - 2026)
Inogen's (INGN) quarterly Liabilities and Shareholders Equity came in at $285.9 million in Q1 2026, down 7.29% year-on-year from $308.4 million in Q1 2025, and down 4.25% on a QoQ basis from $298.6 million in Q4 2025.
Inogen (INGN) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $285.9 million in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 7.29% year-over-year to $285.9 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 1.32% decrease from a year earlier, with the FY2025 full-year figure at $298.6 million, up 0.82% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $285.9 million, down from $298.6 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for INGN reached as high as $474.6 million in Q1 2022 and fell as low as $285.9 million in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $352.2 million across 5 years, with a median of $315.6 million in 2024.
- Across the five-year window, Liabilities and Shareholders Equity fell 26.81% in 2023 and increased 1.01% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $405.0 million in 2022, then dropped by 19.47% to $326.2 million in 2023, then fell by 9.2% to $296.2 million in 2024, then increased by 0.82% to $298.6 million in 2025, then declined by 4.25% to $285.9 million in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $285.9 million in Q1 2026, $298.6 million in Q4 2025, and $307.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | Inogen | 172.68 Mn | 62.51 Mn | 37.86 Mn | 285.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285.93 Mn |
| Dec 31, 2025 | 298.63 Mn |
| Sep 30, 2025 | 307.01 Mn |
| Jun 30, 2025 | 312.04 Mn |
| Mar 31, 2025 | 308.41 Mn |
| Dec 31, 2024 | 296.19 Mn |
| Sep 30, 2024 | 306.17 Mn |
| Jun 30, 2024 | 308.92 Mn |
| Mar 31, 2024 | 315.60 Mn |
| Dec 31, 2023 | 326.19 Mn |
| Sep 30, 2023 | 343.70 Mn |
| Jun 30, 2023 | 374.35 Mn |
| Mar 31, 2023 | 385.67 Mn |
| Dec 31, 2022 | 405.04 Mn |
| Sep 30, 2022 | 469.58 Mn |
| Jun 30, 2022 | 470.07 Mn |
| Mar 31, 2022 | 474.62 Mn |
| Dec 31, 2021 | 489.51 Mn |
| Sep 30, 2021 | 512.86 Mn |
| Jun 30, 2021 | 498.17 Mn |